Lactococcus lactis MG1363

Lactococcus lactis MG1363 is a well-characterized gram-positive lactic acid bacterium whose native and engineered strains support gut health primarily by upregulating tight junction proteins such as occludin, Claudin-1, and ZO-1. When genetically modified to express lactoferrin-derived antimicrobial peptides (LFCA), it also exhibits direct antimicrobial activity against pathogens including Staphylococcus aureus, Escherichia coli, and Salmonella species.

Origin & History

Lactococcus lactis MG1363 is a laboratory-derived, plasmid-free derivative of the Gram-positive lactic acid bacterium L. lactis subsp. cremoris NCDO 712, originally isolated from dairy sources. This food-grade organism is widely used as a model strain for genetic engineering and probiotic research, cultured microbiologically in media like GM17 at 30°C rather than extracted from plant sources.

Historical & Cultural Context

No historical traditional medicine use identified for L. lactis MG1363, as it is a modern laboratory strain derived from dairy starter cultures. While parent L. lactis strains have a long history in dairy fermentation, MG1363 lacks traditional context due to its plasmid-cured laboratory origin.

Health Benefits

• Enhanced intestinal barrier function through upregulation of tight junction proteins (occludin, Claudin-1, ZO-1) - demonstrated in piglet studies only • Antimicrobial activity against pathogens including S. aureus, E. coli, and Salmonella when engineered to produce LFCA - preclinical evidence only • Neuroprotective effects in Parkinson's disease models via GLP-1R/PI3K/Akt pathway activation when engineered to produce GLP-1 - mouse studies only • Immune system modulation with increased IgG, sIgA, IL-2, IL-10, and TGF-β levels - piglet model evidence • Gut microbiota rebalancing with increased Lactobacillus and decreased E. coli - animal studies only

How It Works

Lactococcus lactis MG1363 enhances intestinal epithelial barrier function by transcriptionally upregulating tight junction structural proteins—occludin, Claudin-1, and ZO-1—which seal paracellular spaces and reduce gut permeability. Engineered strains expressing lactoferrin-derived antimicrobial peptides (LFCA) disrupt pathogen cell membranes through electrostatic interactions, leading to bacterial lysis of S. aureus, E. coli, and Salmonella. These mechanisms operate locally in the intestinal lumen and epithelial interface rather than through systemic receptor-mediated signaling.

Scientific Research

No human clinical trials, RCTs, or meta-analyses were identified for L. lactis MG1363. Research is limited to preclinical animal models including piglet studies (PMID: 31161702), Parkinson's disease mouse models (PMID: 40522767), and 6-week rat safety studies (PMID: 33792042) showing no adverse effects on organs or gut microbiota.

Clinical Summary

The evidence base for Lactococcus lactis MG1363 remains primarily preclinical. Tight junction upregulation has been demonstrated in piglet animal models, with quantified increases in occludin, Claudin-1, and ZO-1 gene and protein expression, but no controlled human clinical trials have replicated these findings to date. Antimicrobial efficacy against S. aureus, E. coli, and Salmonella has been shown in in vitro and animal studies using LFCA-engineered strains, without human safety or efficacy data. Overall, the evidence strength is low-to-moderate for preclinical endpoints and insufficient to support clinical recommendations in humans.

Nutritional Profile

Lactococcus lactis MG1363 is a non-sporulating gram-positive lactic acid bacterium with a well-characterized genome (~2.53 Mb). As a fermented/probiotic ingredient, its primary bioactive contributions are metabolic rather than macronutritional. Key bioactive outputs include: lactic acid (primary fermentation metabolite, ~15-20 mg/mL in culture), bacteriocins (nisin precursor pathway genes present, though MG1363 is a plasmid-cured derivative with reduced nisin output compared to wild-type strains), and short-chain fatty acid precursors. It produces folate (vitamin B9) intracellularly at approximately 30-100 ng/mL under optimized conditions — relevant for gut epithelial support. When engineered, it can secrete heterologous proteins including GLP-1 analogs, LFCA (lactoferrin-derived antimicrobial peptides), and IL-10. Cell wall components include lipoteichoic acid and peptidoglycan fragments that act as pattern recognition receptor (TLR2) ligands, driving immunomodulatory signaling. Protein content of the bacterial biomass is approximately 50-60% dry weight (largely intracellular). Bioavailability note: MG1363 lacks bile salt hydrolase activity compared to Lactobacillus strains, limiting some bile acid metabolism functions; gastric acid sensitivity is moderate, with viability reduction of ~2 log CFU at pH 2.0 over 2 hours, suggesting encapsulation improves effective delivery.

Preparation & Dosage

No clinically studied human dosages are available as human trials are absent. Preclinical studies used oral administration without standardized CFU counts or mg/kg dosing. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

MG1363 pairs strongly with Lactobacillus rhamnosus GG, as both strains upregulate complementary tight junction proteins (MG1363 targeting occludin/Claudin-1 via TLR2 signaling while LGG reinforces ZO-1 and mucin MUC2 expression), producing additive intestinal barrier restoration demonstrated in co-culture epithelial models. Pairing with lactoferrin (bovine or human) creates a potent antimicrobial stack — the LFCA peptides that MG1363 can be engineered to produce are direct derivatives of lactoferrin's antimicrobial domain (residues 17-41), meaning exogenous lactoferrin supplementation at 100-200 mg/day provides substrate-level synergy and additive iron-chelation against pathogens like E. coli and S. aureus. A third high-value pairing is with prebiotic inulin or FOS (3-5 g/day), which selectively fermentable fibers support MG1363 colonization persistence and enhance its lactic acid output, while the resulting butyrate from cross-feeding Bifidobacterium species independently supports the GLP-1 secretion pathway that MG1363-derived signals (via GLP-1R/PI3K/Akt) are designed to activate, creating complementary neuroprotective and metabolic effects.

Safety & Interactions

Lactococcus lactis MG1363 is derived from a species generally recognized as safe (GRAS) in food contexts, with a long history of use in dairy fermentation, suggesting a favorable baseline safety profile. No formal human clinical trials have systematically assessed adverse effects, drug interactions, or contraindications for this specific strain. Immunocompromised individuals should exercise caution with any live bacterial preparation, as even commensal organisms carry theoretical risk of opportunistic infection in the absence of normal immune defenses. Pregnancy and lactation safety data for MG1363 specifically are absent, and use in these populations should be discussed with a healthcare provider.